Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stereotactic photodynamic therapy with 5-aminolevulinic acid (Gliolan) in recurrent glioblastoma
2015-002727-25Phase 2Terminated
- Sponsor
- Universitätsklinikum Münster
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of 5-aminolevulinic acid in glioblastoma (GBM) (2 arms), sponsored by Universitätsklinikum Münster. Primary endpoint: Progression-free survival. Started Mar 2017; status: terminated.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2015-002727-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002727-25.